Cargando…
Paradox-driven adventures in the development of cancer immunology and immunotherapy
After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally conside...
Autores principales: | Barham, Whitney, Gicobi, Joanina K., Yan, Yiyi, Dronca, Roxana S., Dong, Haidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997591/ https://www.ncbi.nlm.nih.gov/pubmed/32042862 http://dx.doi.org/10.1016/j.gendis.2019.07.001 |
Ejemplares similares
-
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023) -
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
por: Wen, Ti, et al.
Publicado: (2022) -
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018) -
A Gender Factor in Shaping T-Cell Immunity to Melanoma
por: Dronca, Roxana S., et al.
Publicado: (2015) -
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8(+) T cells via ME1 up-regulation
por: Gicobi, Joanina K., et al.
Publicado: (2023)